Xtandi 40 MG tablet 120S
Ended Awarded
- Contract number
- SPE2DX25F6XPU
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Medical Supply Chain
Troop Support, Department of Defense
- Obligated
- $8,339
Award facts
- Contract value 100% obligated
- $8,339.18 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on July 30, 2025, for 120 tablets of Xtandi 40 mg with a ceiling value of $8,339.18. This firm fixed-price delivery order, which has an ultimate completion date of July 31, 2025, was issued without a set-aside designation and is funded through the Defense Logistics Agency's Medical Supply Chain. The award represents a single delivery order under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA, valued at approximately $500 million and valid through November 2026, which enables the agency to procure a comprehensive range of pharmaceutical products for military healthcare facilities.
Xtandi is a prescription oncology medication used in cancer treatment, and its procurement through the DLA reflects the agency's ongoing mission to supply medications to Department of Defense healthcare sites worldwide. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, leveraging its woman-owned small business status to secure multiple contracts for specialty medications, biologics, and medical consumables across various therapeutic categories. This delivery order exemplifies the operational execution of the DLA's SPE2DB program, through which the agency maintains consistent access to essential pharmaceutical products for military medical facilities.
Quick answers
Who was awarded contract SPE2DX25F6XPU?
SPE2DX25F6XPU was awarded to DMS Pharmaceutical Group Inc. by Medical Supply Chain (Troop Support) on July 30, 2025.
How much is contract SPE2DX25F6XPU worth?
The government has obligated $8,339 on SPE2DX25F6XPU.
Is contract SPE2DX25F6XPU an order under another contract?
Yes. SPE2DX25F6XPU is a delivery order under SPE2DX15D9168, an indefinite delivery contract.
Was contract SPE2DX25F6XPU competed?
The extent of competition for SPE2DX25F6XPU was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award